The authors aimed to analyze the safety and effectiveness of increasing doses of methotrexate (Trexall) in combination with adalimumab (Humira) in early rheumatoid arthritis (RA). The authors found out that increased doses of methotrexate resulted in improved outcome in RA.

This study investigated if initial remission can predict long-term remission (LTR) after etanercept (Enbrel) treatment. 

They found that LTR is more likely if strict disease control is achieved before etanercept withdrawal

This study looked at the link between additional medical conditions and mortality in patients with rheumatoid arthritis (RA). The authors identified a number of specific conditions that significantly increased mortality risk in RA patients.

This trial is examining how effective the drug bempedoic acid is when used with ezetimibe (Zetia) to reduce cholesterol in patients with type 2 diabetes (T2D). The main outcome will be the measurement of patient’s cholesterol as well as heart disease risk, diabetes severity and drug side effects. This study is recruiting in the United States: Lincoln, CA, Miami, FL, Louisville, KY and Suffolk, VA.

This study wanted to find out the effect of the medication sotagliflozin (Zynquista) at different doses on the blood sugar levels and weight of people with type 1 diabetes. The study found that at higher doses, sotagliflozin decreased the blood sugar levels and weight of these patients.

This study investigated the link between glucocorticoid (for example Deltasone, Orasone) use in patients with rheumatoid arthritis and changes in levels of good and bad cholesterol. 

This study evaluated the accuracy of four new predictors of kidney damage and disease are compared to the standard test for patients with Type 2 diabetes (T2D). The authors found that these new predictors were as accurate as the standard test at detecting kidney disease.

This study explored the use of abatacept (ABT, Orencia) with either methotrexate (MTX, Trexall) or tacrolimus (TAC) in rheumatoid arthritis patients who had not responded well to previous drugs. The study concluded that ABT and TAC together showed the best response and could be used together to treat rheumatoid arthritis after other drugs had failed. 

This study examined the disease characteristics and treatment of patients with rheumatoid arthritis plus hepatitis C infection.

This study examined if adding atorvastatin (Lipitor) to irbesartan (Avapro) helped reduce early kidney disease in patients with diabetes.  The authors found that adding atorvastatin reduced a number of symptoms of kidney disease for these patients.